z-logo
open-access-imgOpen Access
Flow Cytometric Analysis of Peripheral Blood and Tumor-Infiltrating Regulatory T Cells in Dogs with Oral Malignant Melanoma
Author(s) -
Mitsuhiro Tominaga,
Yutaka Horiuchi,
Mika Ichikawa,
Masao Yamashita,
Kumiko Okano,
Yuri Jikumaru,
Yoko Nariai,
Tsuyoshi Kadosawa
Publication year - 2010
Publication title -
journal of veterinary diagnostic investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.529
H-Index - 78
eISSN - 1943-4936
pISSN - 1040-6387
DOI - 10.1177/104063871002200317
Subject(s) - foxp3 , melanoma , flow cytometry , malignancy , medicine , immune system , peripheral blood , immunotherapy , cancer , pathology , peripheral blood mononuclear cell , immunology , cancer research , biology , biochemistry , in vitro
It is well known that tumor-infiltrating lymphocytes (TILs) and peripheral blood lymphocytes (PBLs) from patients with advanced-stage cancer have a poor immune response. Regulatory T cells (Tregs), characterized by the expression of a cluster of differentiation 4 and intracellular FoxP3 markers, can inhibit antitumor immunoresponse. In the present study, the prevalence of Tregs in peripheral blood and tumor tissue from dogs with oral malignant melanoma was evaluated by triple-color flow cytometry. The percentage of Tregs in the peripheral blood of the dogs with malignancy was significantly increased compared with healthy control dogs, and the percentage of Tregs within tumors was significantly increased compared with Tregs in peripheral blood of dogs with oral malignant melanoma. This finding suggests that the presence of tumor cells induced either local proliferation or selective migration of Tregs to tumor-infiltrated sites. A better understanding of the underlying mechanisms of Treg regulation in patients with cancer may lead to an effective anticancer immunotherapy against canine malignant melanoma and possibly other tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here